key: cord-0934091-gmzmijic
authors: Kumar Manupati, Vijaya; Schoenherr, Tobias; Wagner, Stephan M.; Soni, Bhanushree; Panigrahi, Suraj; Ramkumar, M.
title: Convalescent plasma bank facility location-allocation problem for COVID-19
date: 2021-10-28
journal: Transp Res E Logist Transp Rev
DOI: 10.1016/j.tre.2021.102517
sha: d9fa8a1da10c759aaa8ab8ad6f4dd9d91598d221
doc_id: 934091
cord_uid: gmzmijic

With convalescent plasma being recognized as an eminent treatment option for COVID-19, this paper addresses the location-allocation problem for convalescent plasma bank facilities. This is a critical topic, since limited supply and overtly increasing cases demand a well-established supply chain to flatten the curve. Within this context, we present a novel plasma supply chain model considering stochastic parameters affecting plasma demand and the unique features of the plasma supply chain. The primary objective is to first determine the optimal location of the plasma banks and to then allocate the plasma collection facilities so as to maintain proper plasma flow within the network. In addition, recognizing the perishable nature of plasma, we integrate a deteriorating rate with the objective that as little plasma as possible is lost. We formulate a robust mixed-integer linear programming (MILP) model by considering two conflicting objective functions, namely the minimization of overall plasma transportation time and total plasma supply chain network cost, with the latter also capturing inventory costs to reduce wastage. We then propose a CPLEX-based optimization approach for solving the MILP functions. The feasibility of our results is validated by a comparison study using the Non-Dominated Sorting Genetic Algorithm-II (NSGA-II) and a proposed modified NSGA-III. The application of the proposed model is evaluated by implementing it in a real-world case study within the context of India. The optimized numerical results, together with their sensitivity analysis, provide valuable decision support for policymakers.

The coronavirus disease 2019 (COVID-19) has created a public health emergency of international magnitude spreading across more than 200 countries and territories around the globe. As of September 24, 2021, the pandemic outbreak counted more than 230 million confirmed cases, and more than 4.7 million reported deaths worldwide (WHO 2021) . India reported the second-highest number of cases (more than 33 million) worldwide, mourning more than 446,000 deaths (WHO 2021) . The rapid surge of coronavirus cases during 2020 across the world, and particularly in India during 2021, inflicted unprecedented pressures to find effective treatment strategies including antiviral drugs, plasma therapy, steroids, vaccines, and other drugs for symptomatic treatment . Convalescent plasma (CP) therapy, which is a standard compatible form of immunotherapy, is currently used as post-exposure prophylaxis and/or treatment of infectious diseases. CP therapy has been applied in previous outbreaks of coronaviruses, such as SARS1 in 2003 and MERS in 2012, yielding positive results in reducing the viral load (Arturo and Pirofski 2020; Cheng et al. 2005; Arabi et al. 2016; Bloch et al. 2020) .

The plasma that is extracted from individuals after having overcome the infection is referred to as convalescent (i.e., "immune") plasma, since it contains antibodies. The treatment with antibodies is currently one of the few short-term treatment strategies to have shown an immediate effect on the immune system . The therapy improves clinical symptoms via neutralizing viremia, is well-tolerated, and has only limited side effects. In most acute viral diseases, viremia usually peaks during the first week and a patient's primary immune response is initiated by day 10-14, which is followed by viral clearance. Considering the infectious process, convalescent plasma therapy is most effective when given early in the course of the disease, during the viremia or seronegative stage, i.e., before day 14 (Zeng et al. 2020) .

CP therapy has been appraised as a treatment of prime importance for COVID-19 patients (Rojas et al. 2020 ). However, due to the surge in COVID-19 cases, the demand for plasma has been outpacing supply, also due to the absence of plasma banks (Gehrie et al. 2020) . It is in these plasma banks where the blood's plasma component from recovered COVID-19 patients is stored (Im et al. 2020) . The question however now arises where these plasma banks should be established so as to be most effective in providing relief. The design of a connected network to cover the demand and supply across the country is thus critical. Such a design can serve as the foundation for providing CP therapy whenever and wherever it is required most, while at the same time considering the plasma's shelf life. In this vein, the plasma itself has properties that make it different from blood, with plasma being more perishable in nature. Specifically, the shelf life of plasma is 40 days, or up to 12 months if stored below -18 degrees Celsius. This necessitates an interconnected supply chain to enable the most effective and efficient distribution of plasma so as to prevent wastage.

Within this challenging context, this study develops a novel plasma supply chain network that facilitates both the location of plasma banks and the allocation of facilities to deliver to these plasma banks. The overriding objective is to determine the optimal distribution of the plasma supply to save lives. Additionally, as per the WHO (2021), plasma collection facilities should be setup as close to the plasma collection point as possible. To achieve this, we develop a multiobjective mixed-integer linear program (MILP) model with the objective to minimize both the overall plasma transportation time and the overall plasma supply chain network cost. Unlike most inventory models in extant research that consider stock items able to being kept in inventory indefinitely, we consider the perishability of plasma and incorporate a deteriorating rate to reduce wastage. Since plasma has only recently been required in such significant quantities, and due to the inhomogeneous escalation in the number of patients, we consider the actual demand as unknown but following a predictable prior distribution. In addition, transportation cost is considered as stochastic, since the demand by hospitals is also variable depending on pandemic situation. Within this setting, we propose a CPLEX-based optimization methodology to facilitate the location of plasma banks. As such, we model a supply chain that includes regional and local hospitals, rather than building new plasma banks, which conserves both time and monetary resources. The objective of the model is to minimize both time and cost, which are dual considerations especially relevant within the context of developing countries. While timely plasma distribution and the associated matching of supply and demand is paramount, developing countries generally do not have the luxury to optimize this objective at all costs, providing the rationale for our dual considerations. Finally, using a real-world case study with the context of India, a developing country, we validate the feasibility of the proposed method by comparing the results with the NSGA-II algorithm. This is followed up with a modified version of NSGA-III specifically designed for the proposed problem. Through these efforts, we aim to contribute to society by proposing a plasma supply chain network model that increase the efficiency and effectiveness of plasma delivery to hospitals in order to save lives.

The remainder of this paper is organized as follows. After a review of the literature in Section 2, Section 3 describes the problem and formulates the mathematical model, including notations and assumptions. Section 4 presents the solution methodologies employed, followed by the application of the proposed model within a real-world context (India) in Section 5. Section 6 presents the results and their discussion, with Section 7 concluding and offering avenues for future research.

COVID-19 has triggered the increased need for Convalescent Plasma (CP) therapy, with however the literature specific to plasma supply chain distribution being scant. This is especially the case within the unprecedented pandemic context. Guidance can however be provided by multi-echelon location allocation models applied in emergencies and the general application of CP therapy. These literatures, which form the basis for our investigation, are reviewed in this section. We commence with a traditional supply chain model and modify it to accommodate the unique features of our current pandemic situation, specifically in terms of supply, demand and distribution considerations given by the unique features of plasma (cf. Stanworth et al. 2020 ).

Our review of the CP therapy literature illustrates its application in prior epidemics, including the severe acute respiratory syndrome (SARS) epidemic in 2002 (Cheng et al. 2005 ) and the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak (Arabi et al. 2016 ). These studies found that CP therapy was responsible for a faster patient recovery rate in comparison to regular drugs. These findings were extended by Beigel et al. (2017) , who examined the efficacy of CP in influenza infection. Within the context of COVID-19, Lu (2020) and Bloch et al. (2020) demonstrated the positive effects of CP therapy in COVID-19 patients, validating its use and importance as a treatment regimen. Similar results were obtained by Duan et al. (2020) , who determined CP as a promising rescue option for severe COVID-19 cases. Not only in line with these encouraging results, Thorpe et al. (2020) noted that the demand for plasma-derived products has increased exponentially over the last ten years, fueling the attention that CP supply chains have been receiving. This emphasis is warranted, since there are multiple organizational challenges associated with the development and implementation of a CP program, including policies for testing and approving plasma donations (Stanworth et al. 2020) . Parallels can be seen in Dhiman et al. (2020) , who focused on the cost-effective collection and supply of blood and its components, and Hamdan and Biabat (2020) , who modelled a blood supply chain under disruption risks. Most recent evidence by Chen et al. (2020) , showing a reduction of 21% in mortality rate for COVID-19 patients with the use of CP therapy, is encouraging. With these promising results and the surge in plasma demand, further guidance is needed for the effective collection and distribution of plasma. We provide such guidance in this paper.

Overall, this stream of research suggests that the collection of plasma and the associated distribution network design within the current pandemic context is a critical undertaking. Since the pandemic is so unprecedented in its magnitude and impact, further insight is needed to respond to this dynamic and novel situation. While prior work can serve as a formidable starting point, it may not be perfectly applicable to our current situation (Stanworth et al. 2020) . Therefore, building on the works reviewed above, we aim to provide such insight for the unique pandemic environment we are currently in. In developing our model, we also consider guidance provided by the WHO (2021) and Stanworth et al. (2020) , as well as the unique dynamics created by the pandemic, such as demand uncertainty for plasma due to new discoveries made at lightning speed. As such, we for instance perform rationality and sensitivity analysis to capture this potential demand uncertainty.

The application of location-allocation models within the context of healthcare and emergency supply chains is well established, with researchers utilizing the location allocation model to design networks for blood banks and hospitals (e.g., Jabbarzadeh et al. 2014; Sharma et al. 2019 ). These models provide valuable guidance for decision makers to conduct effective resource planning, assign donor groups to blood banks and hospital patients, and determine the locations for blood banks or emergency hospitals (e.g., Ramezanian and Behboodi 2017) . The design of networks for effective blood distribution, especially in emergencies, has become a national importance in many countries (Beliën and Forcé 2012) .

Allocation modelling within the context of healthcare has been utilizing multi-objective optimization techniques. Examples include Şahin et al. (2007) , who formulated various mathematical models for the regionalization of blood services in Turkey, and Waldman (2014) , who looked at stockpile location and equipment distribution strategies of essential supplies during the influenza pandemic. This context was also chosen by Mogale et al. (2018) , who applied Paretobased multi-objective algorithms with measured parameters to optimize network cost and total lead time simultaneously. Along similar lines, Sha and Huang (2012) proposed an emergency blood supply scheduling model to assist in times of crisis, taking into account the minimization of transportation cost, moving cost and inventory cost. Mitropoulous et al. (2006) solved a multiobjective optimization problem for locating primary healthcare centers and hospitals using the constraint method. The objectives were to minimize travel distance between assigned facilities and patients, while at the same time ensuring an equitable distribution of the facilities.

Literature leveraging allocation models to offer decision support in emergencies, such as floods, earthquakes or the influenza pandemic, provide a further foundation for our work. Overall, the review of the literature suggests the adaptation of standard supply chain models to the specific needs and requirement of the context considered. The design of blood supply chains in particular has received great interest, providing a sound knowledge base for networks with multiple depots. These designs however cannot be readily applied to the plasma supply network problem needed in our current pandemic. Challenges exist in the form of the limited availability of plasma, its perishable nature, and the absence of fixed plasma depots that meet its special storage needs. For example, Islam et al. (2020) cautions that plasma must be collected, stored and defrosted under optimal conditions within 24 hours and then administered within 40 days. Lengthy distribution delays thus cannot be afforded, necessitating the supply chain network design to enable an efficient and effective distribution of plasma. We capture this in our model by integrating a deterioration rate (Dolgui et al. 2017 ).

In addition, applying our model within the context of India, we develop recommendations for depot locations using ArcGIS software. These depot locations are determined by minimizing overall plasma transportation time and total plasma supply chain network cost. Limited resources in our developing country context substantiate the cost focus, constraining the number of depots to be set up. At the same time, the dire need and distribution speed required substantiate the focus on time. Our mathematical model thus balances demand and supply, while keeping the urgency caused by the worsening pandemic situation in mind.

We build on and extend these works in the present paper by devising a location-allocation model for the stochastic plasma supply chain. To the best of our knowledge, no research has looked at this important and timely location-allocation model within the context of a pandemic. In addition, the proposed model provides a new line of thinking for plasma supply chain design in that it improves efficiency and timely access to high-quality services (cf. Hosseini et al. 2020a) . Due to the current crisis, there is a significant need for a stochastic plasma supply chain model.

We formulate an optimal supply chain model for the collection and distribution of plasma consisting of four echelons: donor groups, plasma collection facilities set up at regional hospitals, plasma banks, and COVID-19 treating hospitals at the local level ( Figure 1 ). Considering the rise in COVID-19 cases and soaring demands for plasma, our model incorporates four primary considerations: (i) satisfying the demand of COVID-19 treating hospitals; (ii) providing adequate transportation means enabling speedy delivery and a minimization of transportation time; (iii) integrating the deterioration rate to prevent wastage of plasma; and (iv) aiming to minimize overall plasma supply chain network cost. The second consideration is given utmost priority considering the life and death situation imposed by the severity of the virus, while however also being cognizant of limited financial resources especially in a developing country context, such as India (cf. Remko, 2020) , and the perishability of plasma. With these considerations, our model has the promise to significantly increase the efficiency of the plasma supply chain and thus reduce mortality. The plasma supply chain model is formulated via a multi-objective MILP model. The process is initiated by assigning donor groups to the plasma collection facility in the designated hospitals.

The plasma is then transported to local hospitals that are in need of such for the treatment of COVID-19 patients, based on the hospitals' estimated demand. Any surplus in plasma is transported via road and/or air transport to plasma banks where it is stored and distributed further to other districts in need, or it is stored for future needs considering the propagated trend of the COVID-19 disease. As such, the plasma from the nearest plasma bank is transported via roadways and/or airways to the regional hospital of the district, and from there to the local hospitals to fulfil their plasma demands. The model however also interconnects the local hospitals and plasma collection facilities for immediate fulfilment of plasma requirements to and from any level/city/district. Since plasma is a perishable product, we have chosen such a complex integrated approach to avoid wastage. Transportation requirements are strategically planned and will be determined via mathematical modelling with cost considerations. As such, we formulate a multiobjective MILP mathematical model considering overall plasma transportation time, overall plasma supply chain network costs, and constraints. The main aim of our model is to determine and specify the location and number of plasma banks, as well as the allocation of the collection facilities to these banks, to minimize transportation time for the entire supply chain network while minimizing cost and wastage. A key challenge is to ensure that the proposed model is both timeand cost-efficient in addressing demand fluctuation.

1. Plasma collection facilities and regional plasma banks have limited capacities 2. The vehicles transporting plasma have a fixed capacity 3. The number of transporting vehicles at each facility and bank is limited 4. There are two types of uncertainty: (a) the uncertainty of plasma demand in each period; and, (b) due to unforeseen conditions, the uncertainty in costs for transporting plasma from the facilities to the plasma banks, and from the plasma banks to the hospitals 5. The location of donor groups and hospitals is fixed 6. The length of each decision period is one day (Milenkovic et al. 2015) 7. There are three types of vehicles with different capacities (Sinha et al. 2021) 8. The collection costs for plasma include maintenance, testing, and component costs

Set of potential locations for a plasma collection facility indexed by Set of potential locations for a regional plasma bank Set of hospitals indexed by ℎ

Time period for plasma production Time period

Cost for opening a plasma collection facility at location Cost for collecting plasma from donor group at location Cost for opening a regional plasma bank at location Cost of transporting plasma from plasma collection facility to regional plasma bank through transportation mode Holding cost for plasma at regional plasma bank ℎ Cost of transporting plasma from plasma collection centre to hospital via ℎ transportation mode

Penalty cost at regional plasma bank ; this is considered to be a large number to prevent plasma shortage; this penalty cost is included to avoid bottleneck situations in the interconnected supply chain network

Travel time between plasma collection facility and regional plasma bank via transportation mode

Distance between plasma collection facility and regional plasma bank Quantity of plasma transported from regional plasma bank to regional hospital in period via transportation mode

Plasma inventory level at regional plasma bank in period

The objective is to determine the optimal allocation of plasma collection facilities and the setup of plasma banks so that both the transportation time of plasma between the various echelons and the overall cost of the plasma supply chain network is minimized. As such, the first objective is the minimization of transportation time. It includes the distance and the travel time, which depends on the transportation mode between plasma collection facilities and regional plasma banks, captured Equals to 1 if the collection facility is opened at location , otherwise 0

Equals to 1 if the plasma bank is opened at location otherwise 0 , Equals to 1 if the donor group is allocated to the collection facility in period , otherwise 0

Equals to 1 if the regional plasma bank is allocated to the collection facility in period otherwise 0 , Number of vehicles required at plasma collection facility in period to transport plasma to regional plasma bank (6) and depicted as a function in equation (7). The second objective is to minimize total plasma supply chain network cost, which consists of opening cost, collection cost, transportation cost, inventory and shortage costs. The opening cost includes the establishment of the plasma collection facilities and the plasma banks presented in equation (8). Equation (9) captures the plasma collection cost from donor groups. Equation (10) addresses the overall transportation cost incurred by plasma transportation from plasma collection facilities to plasma banks, and from plasma collection facilities to local hospitals, considering also the associated uncertainty. The uncertain parameters in the objective function, i.e., , and , were ℎ inspired by Bertsimas and Sim (2004) 

deterministic reflecting nominal conditions with no uncertainty at any plasma bank, plasma collection facility and local hospital; when the parameters are variable, the model acts conservatively. We also consider and as dual auxiliary variables that help in , , ℎ improving the estimation efficiency for the uncertain parameters. Equation (11) captures the inventory cost at a regional plasma bank and the lost cost associated with the deterioration of plasma. Since plasma is a perishable product, we introduce a variable lifetime of inventory to reduce the deterioration rate. After a thorough study on growth rates of microorganisms responsible for deterioration (Juneja and Marks 2006, Mochizuki and Hattori 1987) , we consider the deterioration rate as an exponential function with constants A and B as follows:

(1) ( ) = / where both A and B vary with product type and depend on environmental conditions such as required storing temperature, season, etc. In our model, A represents the initial deterioration rate of plasma as soon as plasma taken from a donor. The dimensional unit of A is the fraction of plasma deteriorating per unit of time. The parameter B captures the time at which the deterioration rate of plasma becomes e times of its initial value. It represents the Remaining Useful Life (RUL) for plasma, after which the plasma should be considered as defective or unfit for consumption. The fraction of plasma units produced at period k that deteriorate in period t is given by

As the deterioration rate increases with time

Produced units either deteriorate or get consumed over time and hence items exceeding a certain time limit cannot be considered, i.e.,

Hence, the holding cost and the lost cost for units produced in period k and stored as inventory

As introduced later in the paper, we further consider shortage cost, disincentivizing not fulfilling the demand depicted in equation (12). Equation (13) 

Subjected to:

≤ ∀ , ,

Constraint (14) limits the opening to only one plasma collection facility at one site. Constraint

(15) ensures that only one facility is assigned to one donor group. The radius of the curvature under which a plasma collection facility should be opened for a donor group is presented in constraint (16). That a facility's plasma donation is assigned to a particular donor group is ensured by constraint (17). Constraint (18) indicates that the capacity of a plasma collection facility is limited.

Constraint (19) ensures that a particular donor group does not donate more than its maximum amount of plasma.

(1 -) (20) articulates the inventory level of plasma at regional plasma bank b. That one plasma bank can only be opened at one site is ensured by Constraint (21). Constraint (22) ensures that only one regional plasma bank is assigned to one collection facility. Constraint (23) limits the radius of the curvature under which a regional plasma bank should be opened. That a regional bank has limited capacity is captured in constraint (24). The balancing of inventory across consecutive periods considering the deterioration in each period is captured in constraint (25).

Constraints (26) and (27) determine the maximum number of available transporting vehicles at plasma collection facilities for the transport of plasma to regional plasma banks and local hospitals, respectively. The maximum number of vehicles available at a plasma bank for the transport of plasma to regional hospitals is determined by constraint (28). The number of vehicles required in each case is captured by constraints (29), (30) and (31), respectively. Constraints (32) and (33) limit the load on each vehicle to transport plasma from plasma collection facilities to plasma banks and hospitals, respectively.

∑∑ ℎ -∑ ℎ ℎ ≥ ∑∑ ∀

,

, ℎ , ℎ ≥ 0 and integer (40)

, ≥ 0

Constraint (34) ensures that the demand for the hospitals needs to be satisfied. Constraint (35) articulates the transfer of surplus plasma to plasma banks, after having fulfilled the demand at local hospitals. The dual auxiliary variables, as mentioned earlier, are depicted as constraints in (36) and (37), respectively. Finally, constraints (38) through (43) 

Mixed Integer Linear Programming formulations are computationally complex. We therefore propose a heuristic with two iterative phases that are performed until an optimal solution set is obtained. While the location phase determines the location coordinates for plasma banks, the allocation phase allocates the plasma collection facilities located in each district to those plasma banks. These two phases are iteratively performed until an optimal solution set is obtained.

The location choices for the plasma banks can have a considerable impact on the entire supply chain in terms of both time and cost. As such, the location of a plasma bank is selected based on

(1) the distance of the plasma bank's location to each plasma collection facility, and (2) the cost of setting up a plasma bank at that location, the transportation time, and the means of transportation available at a particular location. The output of this phase will serve as the input for the allocation phase.

A distance matrix captures the distance between the plasma facilities and the plasma banks. The resultant problem is NP-hard in nature as it is an integration of multiple decision factors including location, inventory, and demand. These factors vary in each decision epoch for each plasma bank and local hospital, rendering the proposed problem stochastic in nature.

Generally, for such a stochastic multi-objective linear programming model, the existing literature primarily adopts heuristic algorithms. Although these algorithms have high computational efficiency, they cannot assure an optimal solution. We therefore utilize IBM ILOG Evolutionary algorithms can solve multi-objective optimization problems by generating nondominated solutions i.e., Pareto frontiers, which are considered as optimal solutions. A wide range of such multi-objective evolutionary algorithms exists, which can be classified into two groups:

NSGA and NSGA-II. While the NSGA group does not provide solution (elitism) conservatism (Srinivas and Deb 1994) , the NSGA-II provides such a elitism mechanism, representing a more realistic capture of associated dynamics. Recent developments in evolutionary algorithms have therefore focused on obtaining Pareto solutions. This is also driven by NSGA-II, a modified version of NSGA, utilizing a non-dominated sorting genetic algorithm (Deb et. al 2000) , which is computationally efficient and less dependent on a sharing parameter for diversity preservation.

This was further extended with the introduction of the multi-objective algorithm NSGA-III (Deb and Jain 2014), which is considered to be even more efficient for solving multi-objective problems.

NSGA-III introduces a clustering operator that replaces the crowding distance operator in NSGA-II. Relying on these recent advances, we propose a problem-specific NSGA-III to generate optimal results through the improvement of the convergence rate. We now proceed with an explanation of the key components of NSGA-III.

Let and be the cardinalities for the source set of and target set , respectively. 

The systematic approach proposed by Das and Dennis (2000) is used for generating reference points in the original NSGA-III. We propose to utilize a uniform design, which aims to determine a set of points that are uniformly distributed over the design space generating uniformly distributed reference points in a sphere | . For this, we = {( 1 , 2 ,…, ) ∑ 

The above equation (44) is a hyper-sphere formula that becomes circular for and = 2 spherical when . = 3

For given reference points represented as , a reference line is defined by 

India was chosen as the illustrative context since this developing country's minute 1.3%

contribution to the healthcare sector out of its total GDP is coupled with its second rank in terms of population (1.3 billion) and first in terms of population density (382 persons per square kilometer). We felt that this context would be particularly receptive to any guidance provided in developing plasma supply chain networks in adverse conditions. In addition, the community spread of COVID-19 has been accelerating. the collection, storage, and management of blood and its products remains a significant challenge (Arcot et al. 2020) . We thus apply our model to the case of India, which especially recently has been suffering from a significant spike in cases.

The number of COVID-19 cases in states and districts as of September 1, 2020, was obtained from covidindia.org, a government-run website. Figure   3 indicates the red zones of all 25 Indian states/Union Territories in which we propose to develop the plasma supply chain network. Table 1 provides a complete list of red-zoned districts and Table   2 summarizes the available medical institutions that can serve as the location for a plasma bank.

The distance parameters and and the data in Tables 1 and 2 are obtained using the ArcGIS Network Analyst Tool. The demand parameters D bt and D ht were collected from the National Blood Transfusion Council (NBTC), capturing information on shipments of plasma units at the aggregate level. This data was collected with respect to each blood group for specific dates across a three-month period. The data also contained information regarding the distribution sites (hospitals), and whether plasma units are distributed to patients or stored in inventory. Further, the available number of doses for each blood group was recorded. Table 3 provides further detail on these datasets obtained. In addition, Table 4 denotes whether the respective parameters were generated or are obtained from external sources. Table 5 defines the parameters settings for the NSGA-II and NSGA-III algorithms. 

Computations for an experimental study of our proposed mathematical model were carried out on a PC with Intel Core i5-4302Y (1.70 GHz, 512 KB L2 cache) having a Windows 10 Home operating system with 8 GB RAM. The Multi-Objective MILP was conducted on CPLEX 12.9 and the optimal cost and time were obtained as depicted in Table 6 . Table 6 . Optimized minimum cost and time using CPLEX

The mathematical model from Section 3 was applied to obtain the optimal number of plasma banks and to allocate the collection facilities to them. The following input parameters were considered:

(1) the location coordinates of district-based plasma collection facilities, (2) the available location coordinates for the plasma banks, (3) the distance between the plasma collection facilities, and (4) the distance between plasma collection facilities and plasma banks.

The optimization of the objective functions led to the location of seven plasma banks that ensure a proper flow of plasma in the supply chain network. Table 5 summarizes the results for the location coordinates of plasma banks and the assigned plasma collection facilities, which is also visualized in Figure 4 . The optimization yielded a total of seven plasma banks, ensuring the proper flow of plasma. As can be seen from 

To assure that the obtained results represent the optimum solution, we conducted a comparison study by applying an evolutionary genetic algorithm, specifically Non-Dominated Sorting Genetic

Algorithm-II (NSGA-II) and NSGA-III, which are the most used multi-objective evolutionary algorithm in the literature (Wang et. al 2019 , Ma et. al 2019 . The comparison presented in Table 8 suggests that the CPLEX optimization is very effective in obtaining the optimal solution, as the resultant total cost is less compared to the NSGA-II (i.e., 0.8% better) and the NSGA-III (i.e., 0.06% better). In addition, the average computational time for CPLEX was less compared to that of the NSGA-II and NSGA-III methods. In particular, CPLEX took 1.3 minutes while the computational time of NSGA-II was noted as 5.4 minutes and for NSGA-III it was noted as 2.8 minutes. 

The parameters represent the rationality index that considers the transportation of and plasma from the collection facility to the plasma bank, and from the collection facility to the local hospitals, respectively. As the rationality index increases, the percentage of donors increases.

Tables 9 and 10 articulate the effects of the rationality indices on the required number of vehicles for transporting plasma from the plasma collection facilities to the plasma banks, and from plasma collection facilities to local hospitals, respectively. As such, the rationality index captures the impact on transportation requirements based on an increase or decrease in donors. This provides guidance for decision makers to play through different scenarios based on the number of donors and the ensuing transportation needs. 

The demand for plasma in this pandemic has become stochastic and the supply is irregular.

Managing the supply to fulfil the required demand is thus not simple. A further complicating factor is that plasma is perishable. As a result, shortages may increase the mortality rate and the cost of plasma therapy. At the same time, plasma donors are a scarce resource. In this model, since historical data was not available, the Bertsimas and Sim (2004) We investigate the sensitivity of the objective function by conducting experiments using different degrees of conservatism for the uncertain parameters considering divergence rates of 5%, 10%, 15%, and 20% variability from their nominal value. As such, due to the uncertain and unprecedented context of the pandemic, the sensitivity analysis allows the variation of the uncertain parameters, so that the impact of potential changes can be investigated and taken into Figures 5 and 6 depict the results for the sensitivity analysis of the proposed model. Figure 5 illustrates the worst value occurring when the degree of conservatism has the maximum value, i.e., when all plasma banks' demand fluctuates from their expected demand. This is represented by =|B|. In the case of transportation cost, as illustrated in Figure 6 , the worst value is obtained before the degree of conservatism reaches the peak value, i.e., =20 < |N|=44. Here, when 20 out of 44 facilities show uncertainty due to the rationality in donor groups, the function exhibits its worst output. Table 11 summaries the effects of the main parameters on the objective functions. As can be seen, as the number of donors increases, a drastic growth is seen in total cost, i.e., a 20% and 30%

increase in demand will result in a 33% and 41% growth, respectively. The increase and decrease in demand illustrate the impact on the objective function, but the percentage change is less in comparison to the donors. This can be explained by the fact that as the number of donors increases, the collection and transportation costs increase as well, resulting in an overall increase in total cost.

In contrast, with an increase in demand, shortages may arise in certain plasma facilities, necessitating the transport of plasma from plasma banks, increasing both transportation time and cost. 

We now proceed with theoretical and managerial implications of our proposed model. The model aids in the smooth transport of plasma across India in time of crisis, focusing on addressing the need for especially every red zone. Considering the perishability of plasma and the current COVID-19 situation characterized by demand surpassing the supply of plasma, locating plasma banks and allocating cities to these banks is a critical decision. This can have fundamental implications for the time needed to provide plasma to patients. Another critical aspect that makes the plasma supply chain network so unique and challenging to design is the perishability of plasma.

We therefore captured the deterioration rate of plasma to minimize wastage, which represents one of our theoretical contributions within the context of COVID-19. This interconnected model can thus help healthcare policymakers to plan and organize the timely transport of plasma. While being of immense practical value, the theoretical advances our paper provides are in the form of our model development, which can serve as a starting for other scholars to design supply chain networks with similar characteristics, such as those for organs and other blood components. Our model highlights that if proper care is not taken, the distribution may be suboptimal leading to plasma spoilage in certain areas and unfulfilled plasma need in others. Therefore, small storage facilities should be set up in each regional and local hospital so that, in case of emergency, there is sufficient availability. In addition, to quickly and efficiently transport the plasma from one place to another in the right amount, the capacity of the available transportation vehicles needs to be accurately considered and defined.

Insights derived from our analysis can be invaluable for decision makers for the design of their supply chains in times of crises. As such, the optimal locations for plasma banks can be determined, and guidance for an optimal allocation is provided. By also considering the cost of storage and transportation renders the model practically applicable. In addition, we captured the challenging contexts of the pandemic situation, which can reflect in demand uncertainty and transportation unavailability. The results obtained from the rationality analysis and the sensitivity analysis can help in tackling such uncertainties by planning for the proper flow of plasma at each echelon. Specifically, the study's rationality analysis can assist decision makers in predicting the number of vehicles required for transportation, with the sensitivity analysis providing insights about the resources required in uncertain situations.

From a theoretical angle, our findings also contribute to the general transportation literature addressing transportation implications of supply chain designs. As such, our results have implications for the design of transportation routes, which is determined based on the results of the location-allocation problem. With the insights generated we for instance extend the work of Hamdan and Diabat (2020) and Liu et al. (2020) . In addition, with our results we offer guidance on the impact that the supply chain design has on transportation costs, as part of the overall plasms supply chain network cost, which we aimed to minimize after minimizing overall plasma transportation time. As such, we extend the large body of work that has considered transportation cost as a critical element (e.g., Kamyabniya et al., 2021; Ramezanian and Behboodi, 2017) .

Furthermore, we offer insight into the effect of decisions on the required number of ambulances and airplanes, providing guidance for transportation and logistics professionals on the resources needed for the transportation network. We believe these decision aspects to be particularly critical in developing countries such as India (cf. Tu et al. 2018) , due to the frequently limited resources devoted to healthcare (in India, it is a merely 1.3% of GDP). Considering such constraints makes the focus on cost minimization paramount. We thus add to the body of literature that has highlighted the unique nature of developing nations (e.g., Fang et al. 2020) , and offer valuable decision support for policymakers in these contexts.

We believe that the implications of the proposed model can help policymakers within the Government of India to tackle some of the challenges associated with the disease. In addition, positive advertisements using hoardings, media exposure, and excerpts in newspapers can spread the word about the benefits of plasma therapy into the treatment regimen of COVID-19 and the crucial need for plasma donations by patients that recovered from COVID-19. A tracking system could be established to contact recovered COVID-19 patients to appeal for the donation of plasma.

Providing a token amount or some sort of recognition as an incentive by the Government of India could further mobilize the donation drive. Apart from this, transportation options to and from the residence to the collection facility will ease the process of donation.

The Indian government has taken a step towards setting up plasma collection facilities in every district to provide an adequate amount of plasma to patients suffering from COVID-19. While the projected demand is high, there has been a significant shortage of donors, also having implications for the lead time and cost of plasma units. This research conceptualized a novel plasma supply chain network considering donor groups, plasma collection facilities (set up at regional hospitals), local hospitals, and plasma banks. To support the Government of India in its decision-making process, a Mixed Integer Linear Programming model was developed with two objective functions,

i.e., the minimization of overall plasma transportation time and overall plasma supply chain network cost. The proposed model determined the optimal location for setting up plasma banks, allocating the plasma facilities to these plasma banks under demand uncertainty, considering transportation time, transporting modes, transportation cost, and holding and lost costs to avoid a plasma shortage. The problem was optimized via CPLEX, with the results then being compared to the results obtained with the NSGA-II and NSGA-III algorithms. In addition, rationality and sensitivity analyses were conducted to examine the impact of the stochastic parameters on solution quality.

While our study was able to provide invaluable guidance for decision makers on how to design the plasma collection and distribution, our research is not void of limitations. First, the conditions and assumptions made in building the model, while reasonable and substantiated, might not capture the true dynamism and complexity of the current unprecedented pandemic environment, especially when it comes to the multitude of uncertainties still pertaining to treatment and immunizations. A lot is still being learned as approaches are implemented. Second, we did not consider a collection facility or a plasma bank being closed due to lockdown measures or other disruptions, which certainly represents a limitation. While this situation is unlikely, since every effort is expected to be expended to keep these life-saving facilities open, we note not considering the closure of facilities as a limitation. And third, while we addressed the important problem of plasma collection and distribution considering time and cost objectives to treat COVID-19 patients, we did not consider how the spread of COVID-19 can be controlled or prevented. As we unfortunately have had to observe, this is a challenging undertaking, and even now more than a

year since the start of the spread, we are still seeing surges in different parts of the world, especially

India. This thus brings our research into focus, in which we aim to offer effective means for the collection and distribution of plasma to people in need.

We foresee multiple extensions of this model. For instance, goal programming can be performed to increase the utility of the model, in addition to considering factors from the donor's viewpoint. Developing evolutionary algorithms for solving large instances and the non-linearity of the problem represent further promising avenues. Lastly, plasma donor's motivators can be studied to increase the likelihood of a potential donor providing plasma.

Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia

Potential challenges faced by blood bank services during COVID-19 pandemic and their mitigative measures: The Indian scenario

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

Supply chain management of blood products: A literature review

The price of robustness

Deployment of convalescent plasma for the prevention and treatment of COVID-19

The convalescent sera option for containing COVID-19

Convalescent plasma as a potential therapy for COVID-19

Use of convalescent plasma therapy in SARS patients in Hong Kong

Normal-boundary intersection: a new method for generating the Pareto surface in nonlinear multicriteria optimization problems

An evolutionary many-objective optimization algorithm using reference-pointbased nondominated sorting approach, part I: solving problems with box constraints

A fast elitist non-dominated sorting genetic algorithm for multi-objective optimization: NSGA-II

Designing an integrated blood plasma supply chain under uncertainty demand of both therapy and medicine

Covid-19 pandemic-response to challenges by blood transfusion services in India: a review report

Optimising integrated inventory policy for perishable items in a multi-stage supply chain

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

The effect of carbon tariffs on global emission control: A global supply chain model

Optimized resource allocation for emergency response after earthquake disasters

Balancing supply and demand for blood during the COVID-19 pandemic

Robust design of blood supply chains under risk of disruptions using Lagrangian relaxation

A qualitative, patient-centered perspective toward plasma products supply chain network design with risk controlling

Blood supply chain management: robust optimization, disruption risk, and blood group compatibility (a real-life case)

Convalescent Plasma therapy in coronavirus disease 2019: A case report and suggestions to overcome obstacles

Convalescent plasma therapy in the treatment of COVID-19: Practical considerations: Correspondence

Dynamic supply chain network design for the supply of blood in disasters: A robust model with real world application

Growth kinetics of Salmonella spp. pre-and post-thermal treatment

A robust integrated logistics model for age-based multi-group platelets in disaster relief operations

Scheduling the distribution of blood products: A vendormanaged inventory routing approach

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

NSGA-II with local search for multi-objective application deployment in multi-cloud

A stochastic model predictive control to heterogeneous rail freight car fleet sizing problem

A biobjective model for the locational planning of hospitals and health centers

Kinetic study of growth throughout the lag phase and the exponential phase of Escherichia coli

Grain silo location-allocation problem with dwell time for optimization of food grain supply chain network

Blood supply chain network design under uncertainties in supply and demand considering social aspects

Research opportunities for a more resilient post-COVID-19 supply chain-closing the gap between research findings and industry practice

Convalescent plasma in Covid-19: Possible mechanisms of action

Locational analysis for regionalization of Turkish Red Crescent blood services

A reactive phase against disruptions for designing a proactive platelet supply network

The multi-period location-allocation problem of engineering emergency blood supply systems

Dynamic temporary blood facility location-allocation during and post-disaster periods

Impact of COVID-19 on logistics systems and disruptions in food supply chain

Strategies for ensuring required service level for COVID-19 herd immunity in Indian vaccine supply chain

Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma

Effects of the COVID-19 pandemic on supply and use of blood for transfusion

Bringing new plasma donors back: testing the efficacy of telephone and e-mail communications with first-time donors

Shipping network design in a growth market: The case of Indonesia

The impact of demand uncertainty on stockpile and distribution decisions during influenza pandemic (Doctoral dissertation

Application of NSGA-II Algorithm for fault diagnosis in power system

World Health Organization, 2020. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19). Interim Guidance, World Health Organization

A dynamic logistics coordination model for evacuation and support in disaster response activities

Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019

Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection

Clinical trial analysis of 2019-nCoV therapy registered in China

Machine learning-based multi-objective optimisation of an aerogel glazing system using NSGA-II-study of modelling and application in the subtropical climate Hong Kong